Tapewire

NYSE · USD

AORT

ARTIVION, INC.

Export transactions ↓
Tapewire entity
4767
SEC CIK
0000784199
Parsed reports
700

Last 12 months

Inside the activity.

0 purchase rows · 64 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 2025024
Dec 202506
Jan 202600
Feb 2026012
Mar 2026013
Apr 202600
May 202600
Jun 202602
Jul 202600
Aug 202604
Sep 202603
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
February 26, 2024 Filed Feb 28, 2024 22:04 UTC
GREEN ANDREW MVP Regulatory
SaleCommon Stock 1,218 $20.27 $24,690.20
Disclosure

SEC source: 0000784199-24-000061 · wk-form4_1709157861.xml · nonDerivative · entry 4

GREEN ANDREW M · CIK 0001191000 · VP Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,544

F2 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 22:04 UTC
GREEN ANDREW MVP Regulatory
SaleCommon Stock 1,185 $20.27 $24,021.25
Disclosure

SEC source: 0000784199-24-000061 · wk-form4_1709157861.xml · nonDerivative · entry 2

GREEN ANDREW M · CIK 0001191000 · VP Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,848

F2 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 22:01 UTC
Stanton Marshall S.SVP, Clinical & MD Affair
SaleCommon Stock 1,448 $20.27 $29,352.55
Disclosure

SEC source: 0000784199-24-000059 · wk-form4_1709157669.xml · nonDerivative · entry 4

Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,685

F2 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 22:01 UTC
Stanton Marshall S.SVP, Clinical & MD Affair
SaleCommon Stock 1,600 $20.27 $32,433.76
Disclosure

SEC source: 0000784199-24-000059 · wk-form4_1709157669.xml · nonDerivative · entry 2

Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,489

F2 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 21:58 UTC
Tyrs FlorianVP, Global Operations
SaleCommon Stock 893 $20.27 $18,103.07
Disclosure

SEC source: 0000784199-24-000057 · wk-form4_1709157504.xml · nonDerivative · entry 1

Tyrs Florian · CIK 0001983377 · VP, Global Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,897

F1 · shares: These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction.

Read SEC document
February 26, 2024 Filed Mar 15, 2024 00:38 UTC Amendment
Horton AmyVP, Chief Accounting Officer
SaleCommon Stock 966 $20.27 $19,581.88
Disclosure

SEC source: 0000784199-24-000156 · wk-form4a_1710463100.xml · nonDerivative · entry 4

Horton Amy · CIK 0001371523 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,888

F5 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. This amendment is being filed to address an administrative error in reporting the number of shares sold in the sell to cover transaction on February 26, 2024. The original Form 4 reported that 980 shares were sold, when in fact, 966 shares were sold.

F3 · balance_after: As a result of the administrative error in reporting the number of shares sold in the sell to cover transactions on February 26, 2024, the number of shares reported as beneficially owned in this amendment reflects an increase in the number of shares reported as beneficially owned in the original Form 4.

Read SEC document
February 26, 2024 Filed Mar 15, 2024 00:38 UTC Amendment
Horton AmyVP, Chief Accounting Officer
SaleCommon Stock 1,168 $20.27 $23,676.64
Disclosure

SEC source: 0000784199-24-000156 · wk-form4a_1710463100.xml · nonDerivative · entry 2

Horton Amy · CIK 0001371523 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132,436

F2 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. This amendment is being filed to address an administrative error in reporting the number of shares sold in the sell to cover transaction on February 26, 2024. The original Form 4 reported that 1,186 shares were sold, when in fact, 1,168 shares were sold.

F3 · balance_after: As a result of the administrative error in reporting the number of shares sold in the sell to cover transactions on February 26, 2024, the number of shares reported as beneficially owned in this amendment reflects an increase in the number of shares reported as beneficially owned in the original Form 4.

Read SEC document
February 26, 2024 Filed Mar 15, 2024 00:36 UTC Amendment
Stanton Marshall S.SVP, Clinical & MD Affair
SaleCommon Stock 1,431 $20.27 $29,007.94
Disclosure

SEC source: 0000784199-24-000154 · wk-form4a_1710462983.xml · nonDerivative · entry 4

Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,726

F5 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. This amendment is being filed to address an administrative error in reporting the number of shares sold in the sell to cover transaction on February 26, 2024. The original Form 4 reported that 1,448 shares were sold, when in fact, 1,431 shares were sold.

F3 · balance_after: As a result of the administrative error in reporting the number of shares sold in the sell to cover transactions on February 26, 2024, the number of shares reported as beneficially owned in this amendment reflects an increase in the number of shares reported as beneficially owned in the original Form 4.

Read SEC document
February 26, 2024 Filed Mar 15, 2024 00:36 UTC Amendment
Stanton Marshall S.SVP, Clinical & MD Affair
SaleCommon Stock 1,576 $20.27 $31,947.25
Disclosure

SEC source: 0000784199-24-000154 · wk-form4a_1710462983.xml · nonDerivative · entry 2

Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,513

F2 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. This amendment is being filed to address an administrative error in reporting the number of shares sold in the sell to cover transaction on February 26, 2024. The original Form 4 reported that 1,600 shares were sold, when in fact, 1,576 shares were sold.

F3 · balance_after: As a result of the administrative error in reporting the number of shares sold in the sell to cover transactions on February 26, 2024, the number of shares reported as beneficially owned in this amendment reflects an increase in the number of shares reported as beneficially owned in the original Form 4.

Read SEC document
February 26, 2024 Filed Mar 15, 2024 00:33 UTC Amendment SaleCommon Stock 1,114 $20.27 $22,582.01
Disclosure

SEC source: 0000784199-24-000152 · wk-form4a_1710462815.xml · nonDerivative · entry 4

Maney Rochelle L. · CIK 0001850597 · VP, Quality

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,518

F5 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. This amendment is being filed to address an administrative error in reporting the number of shares sold in the sell to cover transaction on February 26, 2024. The original Form 4 reported that 1,130 shares were sold, when in fact, 1,114 shares were sold.

F3 · balance_after: As a result of the administrative error in reporting the number of shares sold in the sell to cover transactions on February 26, 2024, the number of shares reported as beneficially owned in this amendment reflects an increase in the number of shares reported as beneficially owned in the original Form 4.

Read SEC document
February 26, 2024 Filed Mar 15, 2024 00:33 UTC Amendment SaleCommon Stock 1,168 $20.27 $23,676.64
Disclosure

SEC source: 0000784199-24-000152 · wk-form4a_1710462815.xml · nonDerivative · entry 2

Maney Rochelle L. · CIK 0001850597 · VP, Quality

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,214

F2 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. This amendment is being filed to address an administrative error in reporting the number of shares sold in the sell to cover transaction on February 26, 2024. The original Form 4 reported that 1,185 shares were sold, when in fact, 1,168 shares were sold.

F3 · balance_after: As a result of the administrative error in reporting the number of shares sold in the sell to cover transactions on February 26, 2024, the number of shares reported as beneficially owned in this amendment reflects an increase in the number of shares reported as beneficially owned in the original Form 4.

Read SEC document
February 26, 2024 Filed Mar 15, 2024 00:31 UTC Amendment
Holloway Jean FSVP, General Counsel
SaleCommon Stock 1,543 $20.27 $31,278.31
Disclosure

SEC source: 0000784199-24-000150 · wk-form4a_1710462676.xml · nonDerivative · entry 4

Holloway Jean F · CIK 0001540065 · SVP, General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 166,852

F5 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. This amendment is being filed to address an administrative error in reporting the number of shares sold in the sell to cover transaction on February 26, 2024. The original Form 4 reported that 1,566 shares were sold, when in fact, 1,543 shares were sold.

F3 · balance_after: As a result of the administrative error in reporting the number of shares sold in the sell to cover transactions on February 26, 2024, the number of shares reported as beneficially owned in this amendment reflects an increase in the number of shares reported as beneficially owned in the original Form 4.

Read SEC document
February 26, 2024 Filed Mar 15, 2024 00:31 UTC Amendment
Holloway Jean FSVP, General Counsel
SaleCommon Stock 1,295 $20.27 $26,251.07
Disclosure

SEC source: 0000784199-24-000150 · wk-form4a_1710462676.xml · nonDerivative · entry 2

Holloway Jean F · CIK 0001540065 · SVP, General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,559

F2 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. This amendment is being filed to address an administrative error in reporting the number of shares sold in the sell to cover transaction on February 26, 2024. The original Form 4 reported that 1,314 shares were sold, when in fact, 1,295 shares were sold.

F3 · balance_after: As a result of the administrative error in reporting the number of shares sold in the sell to cover transactions on February 26, 2024, the number of shares reported as beneficially owned in this amendment reflects an increase in the number of shares reported as beneficially owned in the original Form 4.

Read SEC document
February 26, 2024 Filed Mar 15, 2024 00:29 UTC Amendment
GREEN ANDREW MVP Regulatory
SaleCommon Stock 1,199 $20.27 $24,305.05
Disclosure

SEC source: 0000784199-24-000148 · wk-form4a_1710462542.xml · nonDerivative · entry 4

GREEN ANDREW M · CIK 0001191000 · VP Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,580

F5 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. This amendment is being filed to address an administrative error in reporting the number of shares sold in the sell to cover transaction on February 26, 2024. The original Form 4 reported that 1,218 shares were sold, when in fact, 1,199 shares were sold.

F3 · balance_after: As a result of the administrative error in reporting the number of shares sold in the sell to cover transactions on February 26, 2024, the number of shares reported as beneficially owned in this amendment reflects an increase in the number of shares reported as beneficially owned in the original Form 4.

Read SEC document
February 26, 2024 Filed Mar 15, 2024 00:29 UTC Amendment
GREEN ANDREW MVP Regulatory
SaleCommon Stock 1,168 $20.27 $23,676.64
Disclosure

SEC source: 0000784199-24-000148 · wk-form4a_1710462542.xml · nonDerivative · entry 2

GREEN ANDREW M · CIK 0001191000 · VP Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,865

F2 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. This amendment is being filed to address an administrative error in reporting the number of shares sold in the sell to cover transaction on February 26, 2024. The original Form 4 reported that 1,185 shares were sold, when in fact, 1,168 shares were sold.

F3 · balance_after: As a result of the administrative error in reporting the number of shares sold in the sell to cover transactions on February 26, 2024, the number of shares reported as beneficially owned in this amendment reflects an increase in the number of shares reported as beneficially owned in the original Form 4.

Read SEC document
February 26, 2024 Filed Mar 15, 2024 00:27 UTC Amendment
Davis John EChief Commercial Officer
SaleCommon Stock 1,875 $20.27 $38,008.31
Disclosure

SEC source: 0000784199-24-000146 · wk-form4a_1710462424.xml · nonDerivative · entry 4

Davis John E · CIK 0001653206 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,572

F5 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. This amendment is being filed to address an administrative error in reporting the number of shares sold in the sell to cover transaction on February 26, 2024. The original Form 4 reported that 1,904 shares were sold, when in fact, 1,875 shares were sold.

F3 · balance_after: As a result of the administrative error in reporting the number of shares sold in the sell to cover transactions on February 26, 2024, the number of shares reported as beneficially owned in this amendment reflects an increase in the number of shares reported as beneficially owned in the original Form 4.

Read SEC document
February 26, 2024 Filed Mar 15, 2024 00:27 UTC Amendment
Davis John EChief Commercial Officer
SaleCommon Stock 1,586 $20.27 $32,149.96
Disclosure

SEC source: 0000784199-24-000146 · wk-form4a_1710462424.xml · nonDerivative · entry 2

Davis John E · CIK 0001653206 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 151,711

F2 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. This amendment is being filed to address an administrative error in reporting the number of shares sold in the sell to cover transaction on February 26, 2024. The original Form 4 reported that 1,610 shares were sold, when in fact, 1,586 shares were sold.

F3 · balance_after: As a result of the administrative error in reporting the number of shares sold in the sell to cover transactions on February 26, 2024, the number of shares reported as beneficially owned in this amendment reflects an increase in the number of shares reported as beneficially owned in the original Form 4.

Read SEC document
February 26, 2024 Filed Mar 15, 2024 00:14 UTC Amendment
Mackin James PPresident & CEO
SaleCommon Stock 12,968 $20.27 $262,875.62
Disclosure

SEC source: 0000784199-24-000134 · wk-form4a_1710461680.xml · nonDerivative · entry 4

Mackin James P · CIK 0001408470 · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 696,253

F5 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. This amendment is being filed to address an administrative error in reporting the number of shares sold in the sell to cover transaction on February 26, 2024. The original Form 4 reported that 13,168 shares were sold, when in fact, 12,968 shares were sold.

F3 · balance_after: As a result of the administrative error in reporting the number of shares sold in the sell to cover transactions on February 26, 2024, the number of shares reported as beneficially owned in this amendment reflects an increase in the number of shares reported as beneficially owned in the original Form 4.

Read SEC document
February 26, 2024 Filed Mar 15, 2024 00:14 UTC Amendment
Mackin James PPresident & CEO
SaleCommon Stock 17,868 $20.27 $362,204.01
Disclosure

SEC source: 0000784199-24-000134 · wk-form4a_1710461680.xml · nonDerivative · entry 2

Mackin James P · CIK 0001408470 · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 650,573

F2 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. This amendment is being filed to address an administrative error in reporting the number of shares sold in the sell to cover transaction on February 26, 2024. The original Form 4 reported that 18,144 shares were sold, when in fact, 17,868 shares were sold.

F3 · balance_after: As a result of the administrative error in reporting the number of shares sold in the sell to cover transactions on February 26, 2024, the number of shares reported as beneficially owned in this amendment reflects an increase in the number of shares reported as beneficially owned in the original Form 4.

Read SEC document
February 26, 2024 Filed Mar 15, 2024 00:04 UTC Amendment
Getz Matthew AVP, Human Resources
SaleCommon Stock 1,112 $20.27 $22,541.46
Disclosure

SEC source: 0000784199-24-000126 · wk-form4a_1710461069.xml · nonDerivative · entry 4

Getz Matthew A · CIK 0001784253 · VP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,440

F5 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. This amendment is being filed to address an administrative error in reporting the number of shares sold in the sell to cover transaction on February 26, 2024. The original Form 4 reported that 1,128 shares were sold, when in fact, 1,112 shares were sold.

F3 · balance_after: As a result of the administrative error in reporting the number of shares sold in the sell to cover transactions on February 26, 2024, the number of shares reported as beneficially owned in this amendment reflects an increase in the number of shares reported as beneficially owned in the original Form 4.

Read SEC document
February 26, 2024 Filed Mar 15, 2024 00:04 UTC Amendment
Getz Matthew AVP, Human Resources
SaleCommon Stock 1,168 $20.27 $23,676.64
Disclosure

SEC source: 0000784199-24-000126 · wk-form4a_1710461069.xml · nonDerivative · entry 2

Getz Matthew A · CIK 0001784253 · VP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,140

F2 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. This amendment is being filed to address an administrative error in reporting the number of shares sold in the sell to cover transaction on February 26, 2024. The original Form 4 reported that 1,185 shares were sold, when in fact, 1,168 shares were sold.

F3 · balance_after: As a result of the administrative error in reporting the number of shares sold in the sell to cover transactions on February 26, 2024, the number of shares reported as beneficially owned in this amendment reflects an increase in the number of shares reported as beneficially owned in the original Form 4.

Read SEC document
February 23, 2024 Filed Feb 26, 2024 23:14 UTC
Berry Lance AExecutive VP, CFO
GrantCommon Stock 37,000 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000055 · wk-form4_1708989230.xml · nonDerivative · entry 1

Berry Lance A · CIK 0001478716 · Executive VP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,064

F1 · shares: Represents shares of restricted stock that vest 33 1/3% per year beginning on the first anniversary of the grant date, pursuant to the terms of the Equity and Cash Incentive Plan.

Read SEC document
February 23, 2024 Filed Feb 26, 2024 23:10 UTC
Davis John EChief Commercial Officer
GrantCommon Stock 19,734 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000053 · wk-form4_1708989044.xml · nonDerivative · entry 1

Davis John E · CIK 0001653206 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 147,911

F1 · shares: Represents shares of restricted stock that vest 33 1/3% per year beginning on the first anniversary of the grant date, pursuant to the terms of the Equity and Cash Incentive Plan.

Read SEC document
February 23, 2024 Filed Feb 26, 2024 23:08 UTC
Getz Matthew AVP, Human Resources
GrantCommon Stock 9,250 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000051 · wk-form4_1708988912.xml · nonDerivative · entry 1

Getz Matthew A · CIK 0001784253 · VP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,942

F1 · shares: Represents shares of restricted stock that vest 33 1/3% per year beginning on the first anniversary of the grant date, pursuant to the terms of the Equity and Cash Incentive Plan.

Read SEC document
February 23, 2024 Filed Feb 26, 2024 23:05 UTC
GREEN ANDREW MVP Regulatory
GrantCommon Stock 11,100 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000049 · wk-form4_1708988699.xml · nonDerivative · entry 1

GREEN ANDREW M · CIK 0001191000 · VP Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,667

F1 · shares: Represents shares of restricted stock that vest 33 1/3% per year beginning on the first anniversary of the grant date, pursuant to the terms of the Equity and Cash Incentive Plan.

Read SEC document
February 23, 2024 Filed Feb 26, 2024 23:01 UTC
Holloway Jean FSVP, General Counsel
GrantCommon Stock 19,610 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000047 · wk-form4_1708988421.xml · nonDerivative · entry 1

Holloway Jean F · CIK 0001540065 · SVP, General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 151,468

F1 · shares: Represents shares of restricted stock that vest 33 1/3% per year beginning on the first anniversary of the grant date, pursuant to the terms of the Equity and Cash Incentive Plan.

Read SEC document
February 23, 2024 Filed Feb 26, 2024 22:58 UTC
Horton AmyVP, Chief Accounting Officer
GrantCommon Stock 7,893 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000045 · wk-form4_1708988273.xml · nonDerivative · entry 1

Horton Amy · CIK 0001371523 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,238

F1 · shares: Represents shares of restricted stock that vest 33 1/3% per year beginning on the first anniversary of the grant date, pursuant to the terms of the Equity and Cash Incentive Plan.

Read SEC document
February 23, 2024 Filed Feb 26, 2024 22:55 UTC
Mackin James PPresident & CEO
GrantCommon Stock 89,001 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000043 · wk-form4_1708988118.xml · nonDerivative · entry 1

Mackin James P · CIK 0001408470 · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 628,037

F1 · shares: Represents shares of restricted stock that vest 33 1/3% per year beginning on the first anniversary of the grant date, pursuant to the terms of the Equity and Cash Incentive Plan.

Read SEC document
February 23, 2024 Filed Feb 26, 2024 22:53 UTC GrantCommon Stock 7,893 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000041 · wk-form4_1708987968.xml · nonDerivative · entry 1

Maney Rochelle L. · CIK 0001850597 · VP, Quality

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,016

F1 · shares: Represents shares of restricted stock that vest 33 1/3% per year beginning on the first anniversary of the grant date, pursuant to the terms of the Equity and Cash Incentive Plan.

Read SEC document
February 23, 2024 Filed Feb 26, 2024 22:50 UTC
Stanton Marshall S.SVP, Clinical & MD Affair
GrantCommon Stock 14,800 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000039 · wk-form4_1708987779.xml · nonDerivative · entry 1

Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,703

F1 · shares: Represents shares of restricted stock that vest 33 1/3% per year beginning on the first anniversary of the grant date, pursuant to the terms of the Equity and Cash Incentive Plan.

Read SEC document
February 23, 2024 Filed Feb 26, 2024 22:47 UTC
THOMSON ROBERT CVP Research & Development
GrantCommon Stock 8,165 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000037 · wk-form4_1708987643.xml · nonDerivative · entry 1

THOMSON ROBERT C · CIK 0001980521 · VP Research & Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,291

F1 · shares: Represents shares of restricted stock that vest 33 1/3% per year beginning on the first anniversary of the grant date, pursuant to the terms of the Equity and Cash Incentive Plan.

Read SEC document
February 23, 2024 Filed Feb 26, 2024 22:45 UTC
Tyrs FlorianVP, Global Operations
GrantCommon Stock 6,537 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000035 · wk-form4_1708987478.xml · nonDerivative · entry 1

Tyrs Florian · CIK 0001983377 · VP, Global Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,790

F1 · shares: Represents shares of restricted stock that vest 33 1/3% per year beginning on the first anniversary of the grant date, pursuant to the terms of the Equity and Cash Incentive Plan.

Read SEC document
February 23, 2024 Filed Feb 28, 2024 22:25 UTC
Horton AmyVP, Chief Accounting Officer
GrantCommon Stock 6,418 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000074 · wk-form4_1709159070.xml · nonDerivative · entry 3

Horton Amy · CIK 0001371523 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 138,836

F3 · shares: Represents performance stock units granted on Feb. 22, 2023. Fifty percent (50%) were issued on Feb. 23, 2024. The remaining shares earned in connection with the Feb. 2023 grant will be eligible to vest and be issued as follows: 25% on 02/22/2025; and 25% on 02/22/2026, assuming employment on the relevant vesting date.

Read SEC document
February 23, 2024 Filed Feb 28, 2024 22:25 UTC
Horton AmyVP, Chief Accounting Officer
GrantCommon Stock 3,366 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000074 · wk-form4_1709159070.xml · nonDerivative · entry 1

Horton Amy · CIK 0001371523 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,604

F1 · shares: Represents performance stock units granted on Feb. 22, 2023. One hundred percent (100%) were issued on Feb. 23, 2024.

Read SEC document
February 23, 2024 Filed Feb 28, 2024 22:22 UTC
Mackin James PPresident & CEO
GrantCommon Stock 58,648 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000072 · wk-form4_1709158886.xml · nonDerivative · entry 3

Mackin James P · CIK 0001408470 · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 708,945

F3 · shares: Represents performance stock units granted on Feb. 22, 2023. Fifty percent (50%) were issued on Feb. 23, 2024. The remaining shares earned in connection with the Feb. 2023 grant will be eligible to vest and be issued as follows: 25% on 02/22/2025; and 25% on 02/22/2026, assuming employment on the relevant vesting date.

Read SEC document
February 23, 2024 Filed Feb 28, 2024 22:22 UTC
Mackin James PPresident & CEO
GrantCommon Stock 40,404 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000072 · wk-form4_1709158886.xml · nonDerivative · entry 1

Mackin James P · CIK 0001408470 · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 668,441

F1 · shares: Represents performance stock units granted on Feb. 22, 2023. One hundred percent (100%) were issued on Feb. 23, 2024.

Read SEC document
February 23, 2024 Filed Feb 28, 2024 22:18 UTC
Holloway Jean FSVP, General Counsel
GrantCommon Stock 12,836 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000070 · wk-form4_1709158686.xml · nonDerivative · entry 3

Holloway Jean F · CIK 0001540065 · SVP, General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 168,376

F3 · shares: Represents performance stock units granted on Feb. 22, 2023. Fifty percent (50%) were issued on Feb. 23, 2024. The remaining shares earned in connection with the Feb. 2023 grant will be eligible to vest and be issued as follows: 25% on 02/22/2025; and 25% on 02/22/2026, assuming employment on the relevant vesting date.

Read SEC document
February 23, 2024 Filed Feb 28, 2024 22:18 UTC
Holloway Jean FSVP, General Counsel
GrantCommon Stock 5,386 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000070 · wk-form4_1709158686.xml · nonDerivative · entry 1

Holloway Jean F · CIK 0001540065 · SVP, General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,854

F1 · shares: Represents performance stock units granted on Feb. 22, 2023. One hundred percent (100%) were issued on Feb. 23, 2024.

Read SEC document
February 23, 2024 Filed Feb 28, 2024 22:16 UTC GrantCommon Stock 6,418 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000068 · wk-form4_1709158544.xml · nonDerivative · entry 3

Maney Rochelle L. · CIK 0001850597 · VP, Quality

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,615

F3 · shares: Represents performance stock units granted on Feb. 22, 2023. Fifty percent (50%) were issued on Feb. 23, 2024. The remaining shares earned in connection with the Feb. 2023 grant will be eligible to vest and be issued as follows: 25% on 02/22/2025; and 25% on 02/22/2026, assuming employment on the relevant vesting date.

Read SEC document
February 23, 2024 Filed Feb 28, 2024 22:16 UTC GrantCommon Stock 3,366 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000068 · wk-form4_1709158544.xml · nonDerivative · entry 1

Maney Rochelle L. · CIK 0001850597 · VP, Quality

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,382

F1 · shares: Represents performance stock units granted on Feb. 22, 2023. One hundred percent (100%) were issued on Feb. 23, 2024.

Read SEC document
February 23, 2024 Filed Feb 28, 2024 22:12 UTC
Davis John EChief Commercial Officer
GrantCommon Stock 12,736 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000065 · wk-form4_1709158363.xml · nonDerivative · entry 3

Davis John E · CIK 0001653206 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,423

F3 · shares: Represents performance stock units granted on Feb. 22, 2023. Fifty percent (50%) were issued on Feb. 23, 2024. The remaining shares earned in connection with the Feb. 2023 grant will be eligible to vest and be issued as follows: 25% on 02/22/2025; and 25% on 02/22/2026, assuming employment on the relevant vesting date.

Read SEC document
February 23, 2024 Filed Feb 28, 2024 22:12 UTC
Davis John EChief Commercial Officer
GrantCommon Stock 5,386 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000065 · wk-form4_1709158363.xml · nonDerivative · entry 1

Davis John E · CIK 0001653206 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 153,297

F1 · shares: Represents performance stock units granted on Feb. 22, 2023. One hundred percent (100%) were issued on Feb. 23, 2024.

Read SEC document
February 23, 2024 Filed Feb 28, 2024 22:07 UTC
Getz Matthew AVP, Human Resources
GrantCommon Stock 7,412 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000063 · wk-form4_1709158049.xml · nonDerivative · entry 3

Getz Matthew A · CIK 0001784253 · VP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,535

F3 · shares: Represents performance stock units granted on Feb. 22, 2023. Fifty percent (50%) were issued on Feb. 23, 2024. The remaining shares earned in connection with the Feb. 2023 grant will be eligible to vest and be issued as follows: 25% on 02/22/2025; and 25% on 02/22/2026, assuming employment on the relevant vesting date.

Read SEC document
February 23, 2024 Filed Feb 28, 2024 22:07 UTC
Getz Matthew AVP, Human Resources
GrantCommon Stock 3,366 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000063 · wk-form4_1709158049.xml · nonDerivative · entry 1

Getz Matthew A · CIK 0001784253 · VP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,308

F1 · shares: Represents performance stock units granted on Feb. 22, 2023. One hundred percent (100%) were issued on Feb. 23, 2024.

Read SEC document
February 23, 2024 Filed Feb 28, 2024 22:04 UTC
GREEN ANDREW MVP Regulatory
GrantCommon Stock 6,914 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000061 · wk-form4_1709157861.xml · nonDerivative · entry 3

GREEN ANDREW M · CIK 0001191000 · VP Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,762

F3 · shares: Represents performance stock units granted on Feb. 22, 2023. Fifty percent (50%) were issued on Feb. 23, 2024. The remaining shares earned in connection with the Feb. 2023 grant will be eligible to vest and be issued as follows: 25% on 02/22/2025; and 25% on 02/22/2026, assuming employment on the relevant vesting date.

Read SEC document
February 23, 2024 Filed Feb 28, 2024 22:04 UTC
GREEN ANDREW MVP Regulatory
GrantCommon Stock 3,366 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000061 · wk-form4_1709157861.xml · nonDerivative · entry 1

GREEN ANDREW M · CIK 0001191000 · VP Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,033

F1 · shares: Represents performance stock units granted on Feb. 22, 2023. One hundred percent (100%) were issued on Feb. 23, 2024.

Read SEC document
February 23, 2024 Filed Feb 28, 2024 22:01 UTC
Stanton Marshall S.SVP, Clinical & MD Affair
GrantCommon Stock 10,644 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000059 · wk-form4_1709157669.xml · nonDerivative · entry 3

Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,133

F3 · shares: Represents performance stock units granted on Feb. 22, 2023. Fifty percent (50%) were issued on Feb. 23, 2024. The remaining shares earned in connection with the Feb. 2023 grant will be eligible to vest and be issued as follows: 25% on 02/22/2025; and 25% on 02/22/2026, assuming employment on the relevant vesting date

Read SEC document
February 23, 2024 Filed Feb 28, 2024 22:01 UTC
Stanton Marshall S.SVP, Clinical & MD Affair
GrantCommon Stock 5,386 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000059 · wk-form4_1709157669.xml · nonDerivative · entry 1

Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,089

F1 · shares: Represents performance stock units granted on Feb. 22, 2023. One hundred percent (100%) were issued on Feb. 23, 2024.

Read SEC document
February 23, 2024 Filed Mar 15, 2024 00:38 UTC Amendment
Horton AmyVP, Chief Accounting Officer
GrantCommon Stock 6,418 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000156 · wk-form4a_1710463100.xml · nonDerivative · entry 3

Horton Amy · CIK 0001371523 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 138,854

F4 · shares: Represents performance stock units granted on Feb. 22, 2023. Fifty percent (50%) were issued on Feb. 23, 2024. The remaining shares earned in connection with the Feb. 2023 grant will be eligible to vest and be issued as follows: 25% on 02/22/2025; and 25% on 02/22/2026, assuming employment on the relevant vesting date.

F3 · balance_after: As a result of the administrative error in reporting the number of shares sold in the sell to cover transactions on February 26, 2024, the number of shares reported as beneficially owned in this amendment reflects an increase in the number of shares reported as beneficially owned in the original Form 4.

Read SEC document
February 23, 2024 Filed Mar 15, 2024 00:38 UTC Amendment
Horton AmyVP, Chief Accounting Officer
GrantCommon Stock 3,366 $0.00 $0.00
Disclosure

SEC source: 0000784199-24-000156 · wk-form4a_1710463100.xml · nonDerivative · entry 1

Horton Amy · CIK 0001371523 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,604

F1 · shares: Represents performance stock units granted on Feb. 22, 2023. One hundred percent (100%) were issued on Feb. 23, 2024.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.